MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

47.42 -0.67

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

47.18

Max

48.1

Galvenie mērījumi
By Trading Economics
Ienākumi	34M 22M
Pārdošana	16M 165M
P/E Sektora vidējais	41.391 35.739
Peļņas marža	13.598
Darbinieki	674
EBITDA	20M 38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-0.67% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 3. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	594M 2.7B
Iepriekšējā atvēršanas cena	48.09
Iepriekšējā slēgšanas cena	47.42

Ziņu noskaņojums

By Acuity

50%

183 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. okt. 16:58 UTC

Peļņas

BMW Trims 2025 View, Citing Weaker Performance in China

2025. g. 7. okt. 23:43 UTC

Tirgus saruna

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025. g. 7. okt. 23:36 UTC

Tirgus saruna

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025. g. 7. okt. 23:19 UTC

Tirgus saruna

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025. g. 7. okt. 22:40 UTC

Tirgus saruna

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025. g. 7. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 20:44 UTC

Karstas akcijas

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025. g. 7. okt. 19:42 UTC

Tirgus saruna

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025. g. 7. okt. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025. g. 7. okt. 19:07 UTC

Tirgus saruna

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025. g. 7. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025. g. 7. okt. 16:28 UTC

Peļņas

BMW to Post Full Quarterly Results, Adjusted Outlook on Nov. 5

2025. g. 7. okt. 16:28 UTC

Peļņas

BMW Remains Committed to Share Buyback Program

2025. g. 7. okt. 16:27 UTC

Peļņas

BMW: Dividend Payout Ratio Remains Between 30% and 40% of Net Income Attributable to Shareholders

2025. g. 7. okt. 16:27 UTC

Peļņas

BMW Sees 2025 FCF in Automotive Segment Above EUR2.5B, Prior Above EUR5B

2025. g. 7. okt. 16:26 UTC

Peļņas

BMW Sees Slight Decline in 2025 Group Earnings Before Tax, Prior Forecast on Same Level as 2024

2025. g. 7. okt. 16:25 UTC

Peļņas

BMW Sees 2025 RoCE in Automotive Segment Between 8% and 10%, Prior 9% to 13%

2025. g. 7. okt. 16:25 UTC

Peļņas

BMW: 2025 Auto EBIT Margin Forecast Range Remains Between 5% to 7%, Lower Part More Likely

2025. g. 7. okt. 16:23 UTC

Peļņas

BMW Decided to Reduce Volume Expectations for Chinese Market in 4Q

2025. g. 7. okt. 16:22 UTC

Peļņas

BMW: Targeted Volume Growth in China Remained Below Expectations

2025. g. 7. okt. 16:21 UTC

Peļņas

BMW Cuts 2025 View

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

-0.67% uz leju

Prognoze 12 mēnešiem

Vidējais 47.75 USD -0.67%

Augstākais 63 USD

Zemākais 40 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

183 / 371 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.